Patents by Inventor Tony Yu

Tony Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10980894
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: April 20, 2021
    Assignee: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
  • Publication number: 20210024569
    Abstract: The present disclosure is related to the six isomer structures (OBI-821-1990-V1A, OBI-821-1990-V1B, OBI-821-1990-V2A, OBI-821-1990-V2B, OBI-821-1858-A, and OBI-821-1858-B) of isolated OBI-821 adjuvant and the method for evaluating the quality thereof. The method of the present disclosure adopts hydrophilic interaction liquid chromatography (HILIC) and reverse phase high performance liquid chromatography (RP-HPLC) either alone or in tandem and is able to separate the isomers of OBI-821 adjuvant in the consequent chromatography. Accordingly, the quality of OBI-821 adjuvant can be further evaluated.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 28, 2021
    Applicant: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Yih-Huang Hsieh, Wei Han Lee, Yu Chen Lin, Nan Hsuan Wang
  • Patent number: 10815307
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 27, 2020
    Assignee: OBI Pharma Inc.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Cheng-Chi Wang, Yi-Chien Tsai
  • Publication number: 20200138967
    Abstract: The present disclosure is generally directed to treatment methods and compositions comprising administering anti-SSEA-4 antibodies; alone or in additive and/or synergistic combination with other therapeutic agents in oncology to enhance therapeutic efficacy whereby the interaction alters the epitope binding of Siglec-9 protein; including human Siglec-9 or a mammalian Siglec-9; wherein the use of such anti-SSEA-4 compositions are efficacious in preventing, reducing risk, or treating an individual with cancer.
    Type: Application
    Filed: October 2, 2019
    Publication date: May 7, 2020
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, Yi-Chien TSAI
  • Publication number: 20200062861
    Abstract: The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and/or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perjeta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.
    Type: Application
    Filed: June 27, 2019
    Publication date: February 27, 2020
    Inventors: Cheng-Der Tony YU, Yih Huang HSIEH, Yin-Cheng HSIEH, Teng-Yi HUANG, Yi-Chien TSAI, Nan-Hsuan WANG, Pu-Ling HU
  • Publication number: 20200048334
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 21, 2019
    Publication date: February 13, 2020
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN
  • Patent number: 10517936
    Abstract: The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: December 31, 2019
    Assignee: OBI Pharma., Inc.
    Inventors: Wei Han Lee, Nan-Hsuan Wang, Chung Hao Chang, Yih-Huang Hsieh, Cheng Der Tony Yu, Cheng-Chi Wang, Yu-Hsin Lin, Yu-Chen Lin, I-Ju Chen
  • Publication number: 20190389963
    Abstract: The present disclosure relates to treatment of cancer patients with anti-Globo series antigens (Globo H and SSEA-4) antibodies in combination with anti-negative immune check point antibody to rescue the inhibited T cell activity.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 26, 2019
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, Yi-Chien TSAI, Jo-Fan CHANG
  • Patent number: 10501532
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 10, 2019
    Assignee: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen
  • Publication number: 20180339061
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Application
    Filed: June 1, 2018
    Publication date: November 29, 2018
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
  • Publication number: 20180134799
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 17, 2018
    Inventors: Cheng-Der Tony YU, Jiann-Shiun Lai, I-Ju Chen, Cheng-Chi Wang, Yi-Chien Tsai
  • Patent number: 9902779
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: February 27, 2018
    Assignee: OBI PHARMA INC.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Cheng-Chi Wang, Yi-Chien Tsai
  • Publication number: 20180028629
    Abstract: The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.
    Type: Application
    Filed: July 27, 2017
    Publication date: February 1, 2018
    Inventors: Cheng-Der Tony YU, Peiwen YU, Kuo-Pao LAI, Wei-Han LEE, I-Ju CHEN, Shu-Yi LIN, Yih-Huang HSIEH
  • Publication number: 20170304419
    Abstract: The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.
    Type: Application
    Filed: April 24, 2017
    Publication date: October 26, 2017
    Inventors: Cheng-Der Tony YU, Youe-Kong SHUE, Chen-Hsin LIANG, Peiwen YU, Chwen-Cheng CHEN
  • Publication number: 20170283488
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 5, 2017
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
  • Patent number: 9725660
    Abstract: In one implementation, a method for recovery of crude oil from a production fluid comprising an oil-water emulsion is provided. The method comprises adding a solid hydrophilic compound to the production fluid to form a production fluid-solid hydrophilic compound mixture. The method further comprises separating the production fluid-solid hydrophilic compound mixture to produce an oil phase containing the heavy crude oil and a water phase containing the solid hydrophilic compound. The production fluid-solid hydrophilic compound mixture may be separated by centrifuging the production fluid-solid hydrophilic compound mixture to produce the oil phase and the water phase. After separation, the oil phase may be analyzed to determine at least one of: oil composition, physical properties, and geochemical analysis. The crude oil comprises at least one of heavy crude oil, bitumen or combinations thereof.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 8, 2017
    Assignee: WEATHERFORD TECHNOLOGY HOLDINGS, LLC
    Inventors: Aleksander Gjata, Tony Yu Hung Ma
  • Publication number: 20170101462
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Cheng-Der Tony YU, Jiann-Shiun Lai, I-Ju Chen
  • Publication number: 20170029526
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 10, 2015
    Publication date: February 2, 2017
    Inventors: Cheng-Der Tony YU, Jiann-Shiu LAI, I-Ju CHEN, Cheng-Chi WANG, Yi-chien TSAI
  • Patent number: 9537332
    Abstract: Implementations of the present disclosure involve a system and method for load balancing a string of jars. The temperature and voltage of each jar is measured and a target voltage for the jar is set based on the measured temperature. A current is supplied to the jar in order to maintain, increase, or decrease the jar's voltage.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: January 3, 2017
    Assignee: Canara, Inc.
    Inventors: Stephen D. Cotton, Brian Hanking, Cathy Snetsinger, Jason W. Toomey, Michael Carmel, Tony Yu, Patricio A. Triveri, Douglas Sheppard
  • Publication number: 20160339089
    Abstract: The present disclosure encompasses immunogenic/therapeutic compositions including Globo H-KLH glycoconjugates (OBI-822) and/or therapeutic adjuvants (OBI-821/OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.
    Type: Application
    Filed: September 15, 2015
    Publication date: November 24, 2016
    Inventors: Cheng-Der Tony YU, Yih Huang HSIEH, I-Ju CHEN, Wei-Han LEE, Nan-Hsuan WANG